Moreover, combination of AZD1775 and cisplatin significantly prolonged overall survival in a genetically engineered mouse model of mutant KRAS with concomitant loss of LKB1. Of note, LKB1 is among the frequently mutated genes in NSCLC and commonly co-occurs with KRAS mutations (Richer et al. 2017). This evidence concerns the gene KRAS and non-small cell lung carcinoma.